26 May 2020 - Protara Therapeutics today announced that the U.S. FDA has granted fast track designation to intravenous choline chloride for the treatment of intestinal failure-associated liver disease.
Intravenous choline chloride is the Company’s phase 3 ready investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition who have intestinal failure-associated liver disease.